|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ramalingam SS, Owonikoko TK and Khuri FR:
Lung cancer: New biological insights and recent therapeutic
advances. CA Cancer J Clin. 61:91–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hurria A and Kris MG: Management of lung
cancer in older adults. CA Cancer J Clin. 53:325–341. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Judson I and Kelland LR: New developments
and approaches in the platinum arena. Drugs. 59 (Suppl 4):S29–S38.
2000. View Article : Google Scholar
|
|
6
|
Oliver TG, Mercer KL, Sayles LC, Burke JR,
Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, et
al: Chronic cisplatin treatment promotes enhanced damage repair and
tumor progression in a mouse model of lung cancer. Genes Dev.
24:837–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Valle J, Wasan H, Palmer DH, Cunningham D,
Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira
SP, et al: Cisplatin plus gemcitabine versus gemcitabine for
biliary tract cancer. New Engl J Med. 362:1273–1281. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen DW, Pouliot LM, Hall MD and Gottesman
MM: Cisplatin resistance: A cellular self-defense mechanism
resulting from multiple epigenetic and genetic changes. Pharmacol
Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rosell R, Lord RV, Taron M and Reguart N:
DNA repair and cisplatin resistance in non-small-cell lung cancer.
Lung Cancer. 38:217–227. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei F, Jiang X, Gao HY and Gao SH:
Liquiritin induces apoptosis and autophagy in cisplatin
(DDP)-resistant gastric cancer cells in vitro and xenograft
nude mice in vivo. Int J Oncol. 51:1383–1394. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chaib I, Karachaliou N, Pilotto S, Codony
Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, et
al: Co-activation of STAT3 and YES-associated protein 1 (YAP1)
pathway in EGFR-mutant NSCLC. J Natl Cancer Inst. 109:2017.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang W, Gao Y, Li F, Tong X, Ren Y, Han
X, Yao S, Long F, Yang Z, Fan H, et al: YAP promotes malignant
progression of Lkb1-deficient lung adenocarcinoma through
downstream regulation of survivin. Cancer Res. 75:4450–4457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Karachaliou N, Chaib I, Pilotto S, Codony
J, Cai X, Li X, Marin S, Zhou C, Cao P and Rosell R: 76P An
innovative co-targeting of signal transducer and activator of
transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant
non-small cell lung cancer (NSCLC). J Thorac Oncol. 11 (Suppl
4):S87–S88. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pan D: Hippo signaling in organ size
control. Genes Dev. 21:886–897. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the roots of cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo L and Teng L: YAP/TAZ for cancer
therapy: Opportunities and challenges (Review). Int J Oncol.
46:1444–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Morikawa Y, Heallen T, Each JL, Xiao Y and
Martin JF: Dystrophin-glycoprotein complex sequesters Yap to
inhibit cardiomyocyte proliferation. Nature. 547:227–231. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Britschgi A, Duss S, Kim S, Couto JP,
Brinkhaus H, Koren S, De Silva D, Mertz KD, Kaup D, Varga Z, et al:
The Hippo kinases LATS1 and 2 control human breast cell fate via
crosstalk with ERα. Nature. 541:541–545. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gregorieff A, Liu Y, Inanlou MR, Khomchuk
Y and Wrana JL: Yap-dependent reprogramming of Lgr5+
stem cells drives intestinal regeneration and cancer. Nature.
526:715–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park HW, Kim YC, Yu B, Moroishi T, Mo JS,
Plouffe SW, Meng ZP, Lin KC, Yu FX, Alexander CM, et al:
Alternative Wnt signaling activates YAP/TAZ. Cell. 162:780–794.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang GS: Medical uses of mylabris in
ancient China and recent studies. J Ethnopharmacol. 26:147–162.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu CC, Ko FY, Yu CS, Lin CC, Huang YP,
Yang JS, Lin JP and Chung JG: Norcantharidin triggers cell death
and DNA damage through S-phase arrest and ROS-modulated apoptotic
pathways in TSGH 8301 human urinary bladder carcinoma cells. Int J
Oncol. 41:1050–1060. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang JT, Fan YZ, Chen CQ, Zhao ZM and Sun
W: Norcantharidin: A potential antiangiogenic agent for gallbladder
cancers in vitro and in vivo. Int J Oncol.
40:1501–1514. 2012.PubMed/NCBI
|
|
24
|
Chen QY, Jiao DM, Wang J, Hu H, Tang X,
Chen J, Mou H and Lu W: miR-206 regulates cisplatin resistance and
EMT in human lung adenocarcinoma cells partly by targeting MET.
Oncotarget. 7:24510–24526. 2016.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo J, Wu Y, Yang L, Du J, Gong K, Chen W,
Dai J, Li X and Xi S: Repression of YAP by NCTD disrupts NSCLC
progression. Oncotarget. 8:2307–2319. 2017.PubMed/NCBI
|
|
27
|
Li K, Guo J, Wu Y, Jin D, Jiang H, Liu C
and Qin C: Suppression of YAP by DDP disrupts colon tumor
progression. Oncol Rep. 39:2114–2126. 2018.PubMed/NCBI
|
|
28
|
Lee TF, Tseng YC, Nguyen PA, Li YC, Ho CC
and Wu CW: Enhanced YAP expression leads to EGFR TKI resistance in
lung adenocarcinomas. Sci Rep. 8:2712017. View Article : Google Scholar
|
|
29
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shao DD, Xue W, Krall EB, Bhutkar A,
Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et
al: KRAS and YAP1 converge to regulate EMT and tumor survival.
Cell. 158:171–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hsieh CH, Chao KS, Liao HF and Chen YJ:
Norcantharidin, derivative of cantharidin, for cancer stem cells.
Evid Based Complement Alternat Med. 2013:8386512013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bae JS, Kim SM and Lee H: The Hippo
signaling pathway provides novel anti-cancer drug targets.
Oncotarget. 8:16084–16098. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Ding W, Chen C, Niu Z, Pan M and
Zhang H: Roles of Hippo signaling in lung cancer. Indian J Cancer.
52 (Suppl 1):e1–e5. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Song S, Honjo S, Jin J, Chang SS, Scott
AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, et
al: The Hippo coactivator YAP1 mediates EGFR overexpression and
confers chemoresistance in esophageal cancer. Clin Cancer Res.
21:2580–2590. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xiao L, Shi XY, Zhang Y, Zhu Y, Zhu L,
Tian W, Zhu BK and Wei ZL: YAP induces cisplatin resistance through
activation of autophagy in human ovarian carcinoma cells. Onco
Targets Ther. 9:1105–1114. 2016.PubMed/NCBI
|
|
36
|
Kim MH and Kim J: Role of YAP/TAZ
transcriptional regulators in resistance to anti-cancer therapies.
Cell Mol Life Sci. 74:1457–1474. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ye LY, Hu S, Xu HE, Xu RR, Kong H, Zeng
XN, Xie WP and Wang H: The effect of tetrandrine combined with
cisplatin on proliferation and apoptosis of A549/DDP cells and A549
cells. Cancer Cell Int. 17:402017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rosenbluh J, Nijhawan D, Cox AG, Li X,
Neal JT, Schafer EJ, Zack TI, Wang X, Tsherniak A, Schinzel AC, et
al: β-Catenin-driven cancers require a YAP1 transcriptional complex
for survival and tumorigenesis. Cell. 151:1457–1473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lin L, Sabnis AJ, Chan E, Olivas V, Cade
L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, et al: The Hippo
effector YAP promotes resistance to RAF- and MEK-targeted cancer
therapies. Nat Genet. 47:250–256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng HC: The molecular mechanisms of
chemoresistance in cancers. Oncotarget. 8:59950–59964.
2017.PubMed/NCBI
|
|
41
|
Wang T, Wei J, Qian X, Ding Y, Yu L and
Liu B: Gambogic acid, a potent inhibitor of survivin, reverses
docetaxel resistance in gastric cancer cells. Cancer Lett.
262:214–222. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tian A, Wilson GS, Lie S, Wu G, Hu Z,
Hebbard L, Duan W, George J and Qiao L: Synergistic effects of IAP
inhibitor LCL161 and paclitaxel on hepatocellular carcinoma cells.
Cancer Lett. 351:232–241. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Witta SE, Gemmill RM, Hirsch FR, Coldren
CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita
M, et al: Restoring E-cadherin expression increases sensitivity to
epidermal growth factor receptor inhibitors in lung cancer cell
lines. Cancer Res. 66:944–950. 2006. View Article : Google Scholar : PubMed/NCBI
|
